Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Hein

Showing results (81-90 of 173) with videos related to

Pageof 18
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 21, 2022
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registryVolkmar Müller, Alexander Hein, Andreas D Hartkopf, et al.
Frontiers in Genetics|June 20, 2013
The UGT1A6_19_GG genotype is a breast cancer risk factorChristina Justenhoven, Ofure Obazee, Stefan Winter, et al.
Breast Cancer Research and Treatment|September 26, 2014
Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studiesJessica Salmen, Julia Neugebauer, Peter A Fasching, et al.
The Lancet. Oncology|April 20, 2020
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trialJacobus Pfisterer, Catherine M Shannon, Klaus Baumann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2022
Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast CancerPeter A Fasching, Duan Liu, Steve Scully, et al.
Geburtshilfe Und Frauenheilkunde|October 3, 2022
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANTTobias Engler, Peter A Fasching, Diana Lüftner, et al.
Breast (Edinburgh, Scotland)|March 27, 2025
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence riskVolkmar Müller, Manuel Hörner, Marc Thill, et al.
International Journal of Cancer|June 24, 2015
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto studyAlexander Hein, Diether Lambrechts, Gunter von Minckwitz, et al.
European Journal of Cancer (Oxford, England : 1990)|August 8, 2025
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancerLaura L Michel, Philipp Ziegler, Philipp Kreis, et al.
Breast (Edinburgh, Scotland)|February 14, 2025
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancerChristina B Walter, Andreas D Hartkopf, Alexander Hein, et al.
Pageof 18

Showing results (81-90 of 173) with videos related to

Sort By:
Pageof 18
European Journal of Cancer (Oxford, England : 1990)|June 21, 2022
Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registryVolkmar Müller, Alexander Hein, Andreas D Hartkopf, et al.
Frontiers in Genetics|June 20, 2013
The UGT1A6_19_GG genotype is a breast cancer risk factorChristina Justenhoven, Ofure Obazee, Stefan Winter, et al.
Breast Cancer Research and Treatment|September 26, 2014
Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studiesJessica Salmen, Julia Neugebauer, Peter A Fasching, et al.
The Lancet. Oncology|April 20, 2020
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trialJacobus Pfisterer, Catherine M Shannon, Klaus Baumann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2022
Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast CancerPeter A Fasching, Duan Liu, Steve Scully, et al.
Geburtshilfe Und Frauenheilkunde|October 3, 2022
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANTTobias Engler, Peter A Fasching, Diana Lüftner, et al.
Breast (Edinburgh, Scotland)|March 27, 2025
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence riskVolkmar Müller, Manuel Hörner, Marc Thill, et al.
International Journal of Cancer|June 24, 2015
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto studyAlexander Hein, Diether Lambrechts, Gunter von Minckwitz, et al.
European Journal of Cancer (Oxford, England : 1990)|August 8, 2025
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancerLaura L Michel, Philipp Ziegler, Philipp Kreis, et al.
Breast (Edinburgh, Scotland)|February 14, 2025
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancerChristina B Walter, Andreas D Hartkopf, Alexander Hein, et al.
Pageof 18